241
Views
6
CrossRef citations to date
0
Altmetric
Review Articles

Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias

ORCID Icon, , , , &
Pages 519-524 | Received 18 Feb 2021, Accepted 05 Jun 2022, Published online: 14 Jun 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Patrizio Lancellotti. (2023) Focus on cardiometabolic risk factors. Acta Cardiologica 78:5, pages 515-518.
Read now
André J. Scheen. (2023) Glucose-lowering agents and risk of cardiac arrhythmias. Acta Cardiologica 78:3, pages 377-378.
Read now

Articles from other publishers (4)

Yunwen Xu, Thomas A. Boyle, Beini Lyu, Shoshana H. Ballew, Elizabeth Selvin, Alexander R. Chang, Lesley A. Inker, Morgan E. Grams & Jung-Im Shin. (2024) Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study. Journal of General Internal Medicine.
Crossref
Sijin Wu, Wenzhao Lu, Zhongli Chen, Yan Dai, Keping Chen & Shu Zhang. (2022) Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials. Diabetology & Metabolic Syndrome 14:1.
Crossref
André J. Scheen. (2022) Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: A comprehensive review ranging from sulphonylureas to SGLT2 inhibitors. Diabetes & Metabolism 48:6, pages 101405.
Crossref
André J. Scheen. (2022) Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes & Metabolism 48:6, pages 101390.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.